Melatonin reduces the impairment of axonal transport and axonopathy induced by calyculin A

Journal of Pineal Research

Volumn 50, Issue 3, 2011, Pages 319-327

  Xiong, Yu Fang ^a   Chen, Qing ^b   Chen, Juan ^a   Zhou, Jie ^a   Wang, Hong Xing ^c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c inGenious Targeting Laboratory Inc   (United States)

Author keywords

Axonal transport; Melatonin; Neurofilament; Oxidative stress; Protein phosphatase 2A; Tau

Indexed keywords

CALYCULIN A; MALONALDEHYDE; MELATONIN; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHORUS 32; SUPEROXIDE DISMUTASE; TAU PROTEIN;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ISOTOPE LABELING; MOUSE; NERVE FIBER TRANSPORT; NEUROBLASTOMA CELL; NEUROFILAMENT; NEUROPATHY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANIMALS; AXONAL TRANSPORT; AXONS; BLOTTING, WESTERN; CELL LINE; CELL SURVIVAL; MALONDIALDEHYDE; MELATONIN; MICE; OXAZOLES; SUPEROXIDE DISMUTASE;

EID: 79952575901     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2010.00846.x     Document Type: Article

References (51)

1. GRUNDKE-IQBAL I, IQBAL K, TUNG YC et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 1986; 83:4913-4917.
2. LEE VM, BALIN BJ, OTVOS L JR, et al. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 1991; 251:675-678.
3. SANG H, LU Z, LI Y et al. Phosphorylation of tau by glycogen synthase kinase 3beta in intact mammalian cells influences the stability of microtubules. Neurosci Lett 2001; 312:141-144. (Pubitemid 32972143)
4. IQBAL K, ALONSO ADEL C, CHEN S et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005; 1739:198-210. (Pubitemid 40018538)
5. LEE MK, CLEVELAND DW. Neuronal intermediate filaments. Annu Rev Neurosci 1996; 19:187-217. (Pubitemid 26080827)
6. MILLER CC, ACKERLEY S, BROWNLEES J et al. Axonal transport of neurofilaments in normal and disease states. Cell Mol Life Sci 2002; 59:323-330. (Pubitemid 34169517)
7. STRACK S, WESTPHAL RS, COLBRAN RJ et al. Protein serine/ threonine phosphatase 1 and 2A associate with and dephosphorylate neurofilaments. Brain Res Mol Brain Res 1997; 49:15-28. (Pubitemid 27453110)
8. BAJAJ NP. Cyclin-dependent kinase-5 (CDK5) and amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1:319-327.
9. YANG Y, YANG XF, WANG YP et al. Inhibition of protein phosphatases induces transport deficits and axonopathy. J Neurochem 2007; 102:878-886. (Pubitemid 47057302)
10. ZHOU J, WANG H, FENG Y et al. Increased expression of cdk5/ p25 in N2a cells leads to hyperphosphorylation and impaired axonal transport of neurofilament proteins. Life Sci 2010; 86:532-537.
11. RICHARD S, BRION JP, COUCK AM et al. Accumulation of smooth endoplasmic reticulum in Alzheimer's disease: new morphological evidence of axoplasmic flow disturbances. J Submicrosc Cytol Pathol 1989; 21:461-467. (Pubitemid 19185026)
12. LIU Q, XIE F, SIEDLAK SL et al. Neurofilament proteins in neurodegenerative diseases. Cell Mol Life Sci 2004; 61:3057-3075. (Pubitemid 40104581)
13. BENNECIB M, GONG CX, GRUNDKE-IQBAL I et al. Inhibition of PP-2A upregulates CaMKII in rat forebrain and induces hyperphosphorylation of tau at Ser 262/356. FEBS Lett 2001; 490:15-22. (Pubitemid 32126636)
14. CHOHAN MO, KHATOON S, IQBAL IG et al. Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine. FEBS Lett 2006; 580:3973-3979. (Pubitemid 43946883)
15. KINS S, CRAMERI A, EVANS DR et al. Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J Biol Chem 2001; 276:38193-38200.
16. TANAKA T, ZHONG J, IQBAL K et al. The regulation of phosphorylation of tau in SY5Y neuroblastoma cells: the role of protein phosphatases. FEBS Lett 1998; 426:248-254. (Pubitemid 28198136)
17. ZHU LQ, WANG SH, LING ZQ et al. Effect of inhibiting melatonin biosynthesis on spatial memory retention and tau phosphorylation in rat. J Pineal Res 2004; 37:71-77.
18. SUN L, LIU SY, ZHOU XW et al. Inhibition of protein phosphatase 2A- and protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats. Neuroscience 2003; 118:1175-1182. (Pubitemid 36561203)
19. BRZEZINSKI A. Melatonin in humans. N Engl J Med 1997; 336:186-195. (Pubitemid 27034965)
20. PADILLO FJ, RUIZ-RABELO JF, CRUZ A et al. Melatonin and celecoxib improve the outcomes in hamsters with experimental pancreatic cancer. J Pineal Res 2010; 49:264-270.
21. JUNG-HYNES B, HUANG W, REITER RJ et al. Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res 2010; 49:60-68.
22. JOU MJ, PENG TI, HSU LF et al. Visualization of melatonin's multiple mitochondrial levels of protection against mitochondrial Ca(2+)-mediated permeability transition and beyond in rat brain astrocytes. J Pineal Res 2010; 48:20-38.
23. TAN DX, CHEN LD, POEGGELER B et al. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J 1993; 1:57-60.
24. PARADIES G, PETROSILLO G, PARADIES V et al. Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J Pineal Res 2010; 48:297-310.
25. WANG JZ, WANG ZF. Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol Sin 2006; 27:41-49.
26. ZHOU JN, LIU RY, KAMPHORST W et al. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 2003; 35:125-130. (Pubitemid 36960352)
27. LIU RY, ZHOU JN, VAN HEERIKHUIZE J et al. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab 1999; 84:323-327. (Pubitemid 29036721)
28. FENG Z, QIN C, CHANG Y et al. Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. Free Radic Biol Med 2006; 40:101-109. (Pubitemid 41759407)
29. LI XC, WANG ZF, ZHANG JX et al. Effect of melatonin on calyculin A-induced tau hyperphosphorylation. Eur J Pharmacol 2005; 510:25-30.
30. OLMSTED JB, CARLSON K, KLEBE R et al. Isolation of microtubule protein from cultured mouse neuroblastoma cells. Proc Natl Acad Sci U S A 1970; 65:129-136.
31. LI SP, DENG YQ, WANG XC et al. Melatonin protects SH-SY5Y neuroblastoma cells from calyculin A-induced neurofilament impairment and neurotoxicity. J Pineal Res 2004; 36:186-191. (Pubitemid 38429284)
32. MARKLUND S, MARKLUND G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974; 47:469-474.
33. KOBE H, NAKAI A, KOSHINO T et al. Effect of regular maternal exercise on lipid peroxidation levels and antioxidant enzymatic activities before and after delivery. J Nippon Med Sch 2002; 69:542-548. (Pubitemid 36019059)
34. ACUNA-CASTROVIEJO D, COTO-MONTES A, GAIA MONTI M et al. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 1997; 60:PL23-29.
35. BENITEZ-KING G, TUNEZ I, BELLON A et al. Melatonin prevents cytoskeletal alterations and oxidative stress induced by okadaic acid in N1E-115 cells. Exp Neurol 2003; 182:151-159. (Pubitemid 36776258)
36. PAPPOLLA MA, SOS M, OMAR RA et al. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 1997; 17:1683-1690. (Pubitemid 27089813)
37. JUNG C, YABE JT, SHEA TB. C-terminal phosphorylation of the high molecular weight neurofilament subunit correlates with decreased neurofilament axonal transport velocity. Brain Res 2000; 856:12-19. (Pubitemid 30085506)
38. JUNG C, YABE JT, LEE S et al. Hypophosphorylated neurofilament subunits undergo axonal transport more rapidly than more extensively phosphorylated subunits in situ. Cell Motil Cytoskeleton 2000; 47:120-129.
39. YABE JT, JUNG C, CHAN WK et al. Phospho-dependent association of neurofilament proteins with kinesin in situ. Cell Motil Cytoskeleton 2000; 45:249-262. (Pubitemid 30196641)
40. CASH AD, ALIEV G, SIEDLAK SL et al. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol 2003; 162:1623-1627. (Pubitemid 36512845)
41. STOKIN GB, LILLO C, FALZONE TL et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 2005; 307:1282-1288. (Pubitemid 40299973)
42. WANG JZ, GRUNDKE-IQBAL I, IQBAL K. Restoration of biological activity of Alzheimer abnormally phosphorylated tau by dephosphorylation with protein phosphatase-2A, -2B and -1. Brain Res Mol Brain Res 1996; 38:200-208. (Pubitemid 26168279)
43. MALCHIODI-ALBEDI F, PETRUCCI TC, PICCONI B et al. Protein phosphatase inhibitors induce modification of synapse structure and tau hyperphosphorylation in cultured rat hippocampal neurons. J Neurosci Res 1997; 48:425-438. (Pubitemid 27240814)
44. KATO Y, FUSETANI N, MATSUNAGA S. Calyculin A, a novel antitumour metabolite from the marine sponge Discodermia calyx. J Am Chem Soc 1986; 108:2780-2781. (Pubitemid 16037453)
45. ISHIHARA H, MARTIN BL, BRAUTIGAN DL et al. Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. Biochem Biophys Res Commun 1989; 159:871-877. (Pubitemid 19101063)
46. LIU SJ, WANG JZ. Alzheimer-like tau phosphorylation induced by wortmannin in vivo and its attenuation by melatonin. Acta Pharmacol Sin 2002; 23:183-187.
47. WANG DL, LING ZQ, CAO FY et al. Melatonin attenuates isoproterenol- induced protein kinase A overactivation and tau hyperphosphorylation in rat brain. J Pineal Res 2004; 37:11-16.
48. BIERNAT J, GUSTKE N, DREWES G et al. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 1993; 11:153-163. (Pubitemid 23222542)
49. ARENDT T, HOLZER M, FRUTH R et al. Phosphorylation of tau, Abeta-formation, and apoptosis after in vivo inhibition of PP-1 and PP-2A. Neurobiol Aging 1998; 19:3-13.
50. GONG CX, SINGH TJ, GRUNDKE-IQBAL I et al. Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem 1993; 61:921-927. (Pubitemid 23241228)
51. WATAYA T, NUNOMURA A, SMITH MA et al. High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J Biol Chem 2002; 277:4644-4648. (Pubitemid 34968493)